spec sheet11 rows
PRE-084 is a synthetic, highly selective agonist of the sigma-1 receptor, an endoplasmic reticulum chaperone protein that modulates calcium signaling, neurotrophic factor expression, and cellular stress responses. It is used almost exclusively as a preclinical research tool, where it has produced neurorestorative effects in models of Parkinson disease [1], motor neuron survival in models of amyotrophic lateral sclerosis [2], and antidepressant and anti-amnesic activity [5]. A recurring theme across studies is upregulation of brain-derived neurotrophic factor (BDNF) and downstream trophic pathways [2][3][4].
- Neuroprotective and neurorestorative in multiple preclinical models of neurodegeneration
- Raises BDNF and related neurotrophic signaling
- Antidepressant-like and anti-amnesic effects in animal studies
- Potential autonomic and cardiac effects given sigma-1 distribution
Overview
PRE-084 was developed as a selective probe for the sigma-1 receptor, allowing researchers to isolate the effects of sigma-1 activation from the broader, less specific pharmacology of older sigma ligands. Its most cited findings involve neuroprotection and neurorestoration; chronic treatment improved forelimb use and increased dopaminergic fiber density in a 6-hydroxydopamine model of parkinsonism, effects that were absent in sigma-1 knockout animals [1]. In the wobbler mouse model of motor neuron disease, PRE-084 raised spinal BDNF, improved motor neuron survival, and modulated glial responses [2].
A second body of work links sigma-1 activation to mood, stress resilience, and cognition. In a single-prolonged-stress model of post-traumatic stress disorder, PRE-084 normalized anxiety-like behavior and cognitive deficits through a BDNF-TrkB-ERK signaling cascade [3]. In a cerebral ischemia model it rescued learning and memory and restored BDNF via an NR2A-CaMKIV-TORC1 pathway [4]. Classical work established antidepressant-like and anti-amnesic activity that depended on neurosteroid tone [5].
PRE-084 is not a human medicine and has not been developed as one; interest instead centers on the sigma-1 receptor as a druggable target. It should be regarded strictly as a research chemical, with all current evidence derived from cell and animal studies.
- PRE-084 has no measurable benefit in sigma-1 receptor knockout mice, which is one of the cleanest demonstrations that a drug acts through a single named target.
- Much of its appeal comes from raising BDNF, the same neurotrophic factor associated with exercise and learning.
Mechanism
PRE-084 selectively binds and activates the sigma-1 receptor, a -operated chaperone located at mitochondria-associated endoplasmic reticulum membranes. Activation stabilizes inositol trisphosphate receptors and regulates calcium transfer from the endoplasmic reticulum to mitochondria, dampens cellular stress responses, and promotes expression of neurotrophic factors including and GDNF together with downstream ERK1/2 and signaling [1][2]. In cognitive and mood models, benefits track with a --ERK cascade [3] and with an NR2A-CaMKIV-TORC1 pathway that drives transcription [4]. Effects are abolished by sigma-1 antagonists such as BD1047 and in sigma-1 receptor knockout animals, confirming target specificity [1][4].
receptor fingerprint
Sigma-1 receptorSelective agonist
/ GDNF expressionUpregulation (indirect)
ERK1/2 and pathwaysActivation (downstream)
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
PRE-084 is a research chemical intended only for laboratory use; it is not approved for human consumption and has no established human safety profile. Preclinical studies generally report good tolerability at behaviorally active doses, but the long-term consequences of sustained sigma-1 activation in humans are unknown. Because sigma-1 receptors influence cardiac, autonomic, and immune function, extrapolating animal data to people is not warranted. Anyone encountering this compound should treat it as an experimental substance of unknown risk.
History
PRE-084 was introduced in the 1990s as a selective sigma-1 receptor agonist to probe the physiological roles of this then poorly understood binding site. Over the following two decades it became a standard pharmacological tool in sigma-1 research, featuring prominently in work on neurodegeneration, stress, and memory, and helping to establish the sigma-1 receptor as a candidate therapeutic target in Parkinson disease and amyotrophic lateral sclerosis.
Reputation
Within neuroscience, PRE-084 is respected as a clean, well-characterized sigma-1 agonist and is frequently cited in neuroprotection literature. It carries some name recognition in nootropic communities because of its BDNF-promoting and antidepressant-like effects, but there is no human clinical data and it remains an unapproved experimental compound. Its reputation rests on the strength of its preclinical record rather than on any demonstrated human benefit.
Subjective profileweighing the evidence above
A clean preclinical tool with impressive breadth across neurodegeneration models, and that is where it stops; no person has taken it in a published study. Sigma-1 receptors also sit in cardiac and autonomic tissue, so extrapolating the rodent tolerability is not warranted.
Resources
This entry is here for reference.
Research
- 2002first citedStrain differences in sigma(1) receptor-mediated behaviours are related to neurosteroid levels.
- 2016most recentActivation of Sigma-1 receptor ameliorates anxiety-like behavior and cognitive impairments in a…
- 1.Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.
- 2.Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
- 3.Activation of Sigma-1 receptor ameliorates anxiety-like behavior and cognitive impairments in a rat model of post-traumatic stress disorder.
- 4.Sigma 1 receptor activation regulates brain-derived neurotrophic factor through NR2A-CaMKIV-TORC1 pathway to rescue the impairment of learning and memory induced by brain ischaemia/reperfusion.
- 5.Strain differences in sigma(1) receptor-mediated behaviours are related to neurosteroid levels.
- 6.Brain sigma-1 receptor stimulation improves mental disorder and cardiac function in mice with myocardial infarction.
6 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is PRE-084 a nootropic I can take?
No. It is a laboratory research chemical with no human safety data and no approved use. All evidence comes from cell and animal studies.
What makes PRE-084 interesting to researchers?
It is a highly selective sigma-1 receptor agonist that reliably increases BDNF and protects neurons in models of Parkinson disease, ALS, ischemia, and stress.
Does it work through a single target?
Its effects disappear in sigma-1 knockout animals and are blocked by sigma-1 antagonists, indicating a clean, single-target mechanism.
Limitations of the evidence
- No established human safety profile
- Unknown long-term effects of sustained sigma-1 activation
Adverse effects
- Potential autonomic and cardiac effects given sigma-1 distribution